## Abstract The EUROGIN 2010 roadmap represents a continuing effort to provide and interpret updated information on cervical cancer screening and vaccination against the cause of the disease, highβrisk human papillomavirus (HPV). Contrary to the two previous reports in 2008 and 2009, the present ro
EUROGIN 2008 roadmap on cervical cancer prevention
β Scribed by Silvia Franceschi; Jack Cuzick; Rolando Herrero; Joakim Dillner; Cosette M. Wheeler
- Book ID
- 102270798
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- French
- Weight
- 229 KB
- Volume
- 125
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The EUROGIN 2008 Roadmap represents a continuing effort to provide updated information on primary and secondary prevention of cervical cancer. The report addresses several areas including the progress made toward global implementation of currently licensed human papillomavirus (HPV) vaccines, the possibilities and value of futureβgeneration HPV vaccines, endpoints under consideration for evaluation of candidate HPV vaccines, and monitoring impact of HPV vaccination programmes that can be implemented within developed and lessβdeveloped countries. For the sake of completeness, a short update on the evolution of HPV testing in primary screening programmes at present and after HPV vaccine introduction has also been included. The report is available on the EUROGIN website (www.eurogin.com). Β© 2009 UICC
π SIMILAR VOLUMES
Cervical carcinoma (CC) remains a significant health problem in the United States ( U S ) despite the progressive fall in the mortality rate during the past 60 years. However, CC is still the most common cancer among women worldwide and the leading cancer cause of death in many countries. In the U.S
## Abstract ## BACKGROUND: Implementation of the Breast and Cervical Cancer Prevention and Treatment Act of 2000 (BCCPTA) allowed states to extend Medicaid to any woman aged <65 without insurance screened and found to need treatment either for breast or cervical cancer or for a precancerous cervic